Home > Insider Trading > Filing (0001209191-19-053286)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
914475	Neurocrine Biosciences Inc	NBIX	Biological Products, (No Disgnostic Substances) (2836)	330525145

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1557146	Malcolm Lloyd-Smith	12780 El Camino Real San Diego CA 92130	Chief Regulatory Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-10-14	9,956	$15.45	29,569	No	4	M	Direct
Common Stock	Disposition	2019-10-14	9,956	$90.85	19,613	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option	Disposition	2019-10-14	9,956	$15.45	9,956	$15.45

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2024-10-01	No	4	M	Direct

Footnotes

Includes a total of 375 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan. 190 shares were purchased on February 28, 2019 and 185 shares were purchased on August 30, 2019.
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $90.05 to $91.70 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Option granted October 1, 2014 and vested at 25% upon first anniversary (October 1, 2015) and remaining 75% vested in 36 equal monthly installments beginning November 1, 2015.